Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about experiences with Kintor's KX-826 for hair loss, specifically regarding side effects. Some users reported side effects from grey market versions, questioning their authenticity.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

The conversation is about the availability of a 2% Pyrilutamide treatment by Kintor for hair loss. A user confirms that it is not available.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.

Potential cures for Androgenic Alopecia, specifically Kintor/HMI 115, CosmeRNA, Minoxidil and Finasteride.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about choosing between gray market Pyrilutamide and the official Kintor version for hair loss treatment. Users share mixed experiences, with some finding both versions effective and others not seeing results.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

The user is exploring KX-826 as a potential hair loss treatment due to intolerance to FDA-approved drugs like Minoxidil and finasteride. They seek fundamental help and information about KX-826.